加替沙星治疗肺部感染效果观察

目的评价加替沙星序贯治疗急性下呼吸道细菌感染的的临床疗效与安全性。方法采用随机对照法,经临床确诊的急性下呼吸道感染患者共69例,其中加替沙星组35例,给予加替沙星注射液400mg,每日1次静脉滴注,共3～5日,继续以每日加替沙星片400mg,口服每日1次;头孢曲松 红霉素组34例,给予头孢曲松1g,静脉滴注每日1次,红霉素注射液2g静滴,每日2次,总疗程均为7～14天。结果加替沙星组和头孢曲松 红霉素组痊愈率分别为82.8%和76.5%,有效率分别为94.2%和90.2%,两组细菌清除率分别为89.3%和84.0%,两组间临床疗效和细菌学疗效差异无统计学意义,两组的不良反应发生率分别为14.3%.和20.6%。结论加替沙星静脉口服序贯给药治疗下呼吸道感染安全有效。

Clinical observation of Gatifloxacin in the treatment of acute lower respiratory tract bacterial infections

Objective To evaluate the efficacy and safety of Gatifloxacin in the treatment of acute lower respiratory tract bacterial infections using introvenous to oral step down therapy. Methods Sixty-nine patients clinically diagnosed as acute lower respiratory tract bacterial infections were randomly devided into two groups, thirty-five cases treated with Gatifloxacin (experimental group)were compared with 34 cases treated with Ceftriaxone plus Torlamician(control group). In experimental group, Gatifloxacin were first administered intravenously at a dose of 400 mg, once a day for 3~5 days, then taked orally at a dose of 400 mg of Gatifloxacin, once a day. In control group, Ceftriaxone were administered intravenously at a dose of 1 g, once a day and Torlamician at a dose of 2 g, q12h. The total period of treatment in both groups were 7~14 days. Results The overall clinical efficacious rates and cure rates in experimental group was 94.2%, 82.8% and 90.2%, 76.5% in control group, there was no significant difference(P>0.05) between two groups in the clinical efficacy rates and cure rates. Also no significant difference (89.3% to 84.0%, P>0.05) between Gatifloxacin and Ceftriaxone plus Torlamician in the bac terial clearance rates was observed. The incidence of adverse drug reactions for experimental group and control group was 14.3%and 20.6%, respectively(P>0.05). Conclusions Gatifloxacin is an effective and safe antibiotics for the treatment of acute lower respiratory tract bacterial infection using introvenous to oral step down therapy.